Organogenesis Holdings (ORGO) Securities Class Action Investigation

Shamis & Gentile, P.A. is investigating claims on behalf of investors of Organogenesis Holdings Inc. ("Organogenesis Holdings" or the "Company") (ORGO). Impacted investors are advised to contact the firm now.

On September 25, 2025, after market close, Organogenesis Holdings announced that the second Phase 3 trial of ReNu did not achieve statistical significance for its primary endpoint. Following this disclosure, the Company’s stock fell $0.58 per share, or 12.39%, to close at $4.10 on September 26, 2025.

Attorneys are investigating the series of statements Organogenesis Holdings made about the clinical development and regulatory prospects of its ReNu product between May 2024 and September 2025. Earnings releases and investor presentations may have over emphasized the success of the first Phase 3 trial and expressed confidence in ReNu’s potential. The investigation will determine whether the Company’s disclosures during this period fully reflected the risks and uncertainties related to replicating clinical results in the second Phase 3 trial. The investigation also examines whether public statements provided an accurate view of trial progress and data.

If you purchased Organogenesis Holdings (NASDAQ: ORGO) between May 2024 and September 2025, you may be eligible to seek compensation for your losses. Contact Shamis & Gentile today to discuss your options.

Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.

Attorney advertising. Prior results do not guarantee similar outcomes.